This is an editorial summary of research originally reported by Medical Xpress – Health. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
Free weekly digest
We track health and safety research on food, cosmetics, and household products and send you what matters. Join 27 readers.
What would you like to do next?
I use this product
Get the next safety alert before it goes viral
Free weekly digest of health findings about everyday products. No spam, unsubscribe any time.
Advertisement
Get the latest health findings delivered to your inbox. Only the important stuff. No spam.
We'll send a confirmation email. Unsubscribe anytime.
People with obesity who have bariatric surgery see greater long-term reductions in heart disease risk compared to those taking GLP-1 weight-loss medications, according to a new study. Both treatments improve heart health, but surgery delivered stronger protection against future cardiovascular problems. If you're considering obesity treatment options, these findings can help you weigh the long-term heart benefits of each approach.
# Editorial Summary
People struggling with obesity have two main medical options to improve their health: weight-loss surgery or medications like GLP-1 drugs (such as Ozempic and Wegovy). A new study from Mayo Clinic compared how well these approaches work and found that both can benefit heart health, but bariatric surgery appears to offer significantly greater protection against cardiovascular disease over the long term. This research, published in the Annals of Surgery, provides important evidence to help patients and doctors make informed treatment decisions.
The study directly evaluated metabolic and bariatric surgery, procedures that physically alter the digestive system to reduce food intake, against GLP-1 medications, which are increasingly popular as a non-surgical weight-loss option. While both treatments improved cardiovascular health markers in people with obesity, those who underwent surgery showed notably larger reductions in their overall risk of developing heart disease and related complications down the road. This suggests that for some patients, the more invasive surgical approach may offer better long-term heart protection.
It's important to note that surgery and medication each come with their own trade-offs. Bariatric surgery requires a major operation with recovery time and potential complications, while GLP-1 medications are less invasive but must be taken long-term and can be expensive. For consumers considering obesity treatment, the takeaway is to discuss both options thoroughly with your doctor. Your choice should weigh the cardiovascular benefits found in this research against your personal health status, lifestyle, risk tolerance, and whether you can access and afford either option. Individual factors matter, what's best for one person may not be best for another.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
Medical Xpress – HealthWas this finding useful?
Community discussion
Join the discussion
Comments are reviewed before appearing publicly.